Biosimilar Patent Litigation: Analyzing the BPCIA’s Impact on Biologics and Post-Grant Challenges
Welcome to the most recent quarterly update surrounding biologics and biosimilars, with specific focus on post-grant and patent litigation challenges to globally recognized biologics. A note of interest: since the implementation of the Biologics Price Competition and Innovation Act (BPCIA), 43 biosimilars have received approval, with 37 having officially launched. The BPCIA has played a…